abstract OBJECTIVES: Newborn screening for severe combined immunodeficiency (SCID) was instituted in California in 2010. In the ensuing 6.5 years, 3 252 156 infants in the state had DNA from dried blood spots assayed for T-cell receptor excision circles (TRECs). Abnormal TREC results were followed-up with liquid blood testing for T-cell abnormalities. We report the performance of the SCID screening program and the outcomes of infants who were identified.
Severe combined immunodeficiency (SCID) encompasses ∼20 known (and additional unknown), rare genetic disorders of adaptive immunity. Individuals who are affected lack T lymphocytes and have absent or nonfunctional B lymphocytes, rendering them susceptible to lifethreatening bacterial, fungal, and viral infections with both ordinary and opportunistic pathogens.
1,2 Because ,20% of case patients with SCID have a recognized positive family history and because infants who are affected appear healthy at birth, population-based newborn screening (NBS) is the only strategy to identify all infants with SCID sufficiently early to provide treatment before the onset of infectious complications.
3-7
Treatment of SCID most often requires an allogeneic hematopoietic cell transplant (HCT) from a suitably matched healthy donor; in addition, enzyme replacement therapy (ERT) is available for adenosine deaminase (ADA)-deficient SCID, and autologous hematopoietic cell correction by gene therapy (GT) has been successful for ADA-deficient and X-linked SCID.
1,2,7-10 Best outcomes are achieved if infants are treated early to avoid infectious complications, as documented in single-center reports and by multicenter studies from the Primary Immune Deficiency Treatment Consortium (PIDTC).
2,4,7,11
The PIDTC has established laboratory-based definitions for SCID independent of complications, such as opportunistic infections or failure to thrive. 12 Infants with typical SCID have ,300 autologous T cells per mL, absent naïve T cells, and proliferative responses to the mitogen phytohemagglutinin that are ,10% of control values. They often have spontaneous engraftment of maternal T cells, and the diagnosis is further confirmed by documenting pathogenic mutations in known SCID genes. In addition, some infants have hypomorphic mutations in SCID genes that allow residual function and produce a leaky phenotype. These infants usually have ,1500 autologous T cells per mL unless there has been oligoclonal proliferation of memory phenotype T cells, as occurs in Omenn syndrome; infants with leaky SCID generally have sufficient T-cell function to prevent maternal engraftment, but immunity is insufficient to fight infections.
The timely presymptomatic diagnosis of SCID is the primary goal of SCID NBS. California instituted populationwide screening for SCID in August 2010, following pilot programs in Wisconsin, Massachusetts, and the Navajo Reservation and on the recommendation by the Advisory Committee on Heritable Disorders in Newborns and Children (endorsed by the Secretary of the Department of Health and Human Services) that screening for SCID be added to the Recommended Uniform Screening Panel. [13] [14] [15] [16] The SCID NBS test is based on detection of T-cell receptor excision circles (TRECs), DNA biomarkers of normal T lymphopoiesis that can be measured by a polymerase chain reaction test by using dried blood spots (DBSs) routinely obtained from newborns by heel stick. 3 DBSs from newborns with SCID have undetectable or low numbers of TRECs. Moreover, a low TREC copy number in a DBS is used to detect not only the primary screening target, SCID, but also several non-SCID conditions characterized by T-cell lymphopenia (TCL) that may also benefit from early diagnosis and intervention to prevent infections.
In 2014, researchers of an analysis of early pooled data from 11 screening programs endorsed the effectiveness of TREC screening. 17 Although TRECbased SCID screening was highly effective for the diagnosis of SCID in all participating programs, the lack of uniformity in assay methodology between the programs precluded determination of rates of recall for further testing. As of December 10, 2018, all 50 states in the United States, plus the District of Columbia and Puerto Rico, as well as an increasing number of countries, including Israel, New Zealand, and Norway, have adopted universal NBS for SCID. Additional regional or pilot programs are under way in many other countries. Here we report the experience and outcomes of 6.5 years of screening .3.25 million newborns for SCID in California, the state with the largest number of births and high ethnic diversity.
METHODS
Details of methods, including the statistical analysis, are in the Supplemental Information. Briefly, DBS specimens collected from essentially all infants born in California since mid-2010 had TREC testing for SCID, initially with a laboratory-developed assay at the Genetic Disease Laboratory (GDL) in Richmond, California, as published. 18 The EnLite neonatal TREC kit (PerkinElmer, Inc, Waltham, MA) was adopted in June 2015, after which testing moved to regional NBS laboratories. Reported TREC and b-actin copy numbers differed between these methods, requiring adjustment of thresholds. The categories of test results are summarized in Table 1 . After 1 positive or 2 incomplete TREC test results, infants had liquid blood analyzed for lymphocyte subsets and naïve and memory T-cell markers at a single laboratory (Quest Diagnostics, San Juan Capistrano, CA). 19 Children with SCID or TCL detected by NBS were managed until resolution or for at least 1 year and up to 7.5 years. Diagnoses were established by standard clinical testing, including gene sequencing, except as noted below.
RESULTS
Between August 15, 2010, and March 31, 2017, a total of 3 252 156 newborns had SCID screening. Of these, 562 (1 of 5800 total births) had nonnormal TREC results followed by liquid blood lymphocyte phenotyping by flow cytometry (Fig 1A) . Although only 9% of all infants were in NICUs, this population had over half of the TREC-positive screening results (53%; n = 298; Fig 1B) . Cases were tracked to establish diagnoses of both the primary target of screening, SCID, and non-SCID TCL of ,1500 T cells per mL, a clinically important secondary target. This T-cell cutoff was chosen to be highly selective but to avoid exposing infants with significant immune compromise to the otherwise-mandated live, attenuated rotavirus vaccine, which can cause serious diarrhea in immunodeficiency.
20 TCL was documented in 38% (n = 213) of the cohort of infants requiring follow-up flow-cytometry tests or in 1 per 15 300 total newborns (95% confidence interval [CI] 1 per 13 500-1 per 17 700). An urgent positive TREC result (Table 1) was a specific predictor of both SCID and non-SCID TCL; of the 82 newborns with urgent positive results, 38 (46%) had SCID and 21 (26%) had non-SCID TCL. Positive or incomplete TREC test results and documented TCL in those infants who had abnormal TREC test results were more common in infants born very prematurely, as assessed by gestational age (GA) at birth or by birth weight (Tables 2 and 3; see  Supplemental Information for further  details) . Ethnicity and sex were not significant risk factors for having a positive or incomplete TREC result or TCL (data not shown). TREC screening identified 50 cases of SCID (1 per 65 000 births [95% CI 1 per 51 000-1 per 90 000]), 44 cases from regular nurseries and 6 cases from NICUs. The proportions of case patients with true SCID in NICUs was the same as in regular nurseries (Fig 1  B and C) . The 162 cases of non-SCID TCL were categorized as congenital syndromes (72 cases), including multisystem congenital abnormalities with TCL and non-SCID single-gene primary immunodeficiencies; as TCL resulting from another condition and resolving once that condition was corrected (25 cases); as preterm birth alone, in which TCL was self-limited if the infant survived (33 cases); or as idiopathic TCL (33 cases).
Cases of SCID
Of the 50 infants with an immunophenotype of SCID, 49 were immediately hospitalized at an immunodeficiency center for treatment with allogeneic HCT, autologous corrected cell GT, or ERT (Table 4) . One infant with SCID born to a foreign visitor left the United States before receiving any further immune evaluation or treatment. All infants with SCID were healthy at diagnosis except for 2 who had already been brought to medical attention with infection or rashes and 1 who was born prematurely and had feeding intolerance, bronchiolitis, and leukopenia. 21 Only 2 were known by providers at birth hospitals to be at risk for SCID because of a positive family history, whereas 7 others who were identified by SCID NBS had older relatives who were affected and diagnosed with SCID, and 1 had a sibling who had died of infantile pneumonia consistent with SCID. The median age at flow cytometry for infants lacking a recognized family history of SCID was 21 days (range 6-40 days).
Of the 49 patients who were evaluable and treated (Table 4) , 46 survived (94%). Of the 3 deaths, 1 The 9 infants with ADA-deficient SCID had, in addition to lymphopenia of T, B, and natural killer (NK) cells, fewer neutrophils (mean 986 cells per mL) and monocytes (mean 372 cells per mL) than the other infants with SCID, who had means of 4700 neutrophils per mL and 1600 monocytes per mL, or healthy infants. Interestingly, the birth weights of infants with ADAdeficient SCID (median 2608 g) also tended to be lower than those of other infants with SCID (median 3288 g), perhaps reflecting that ADA deficiency is a systemic disorder of purine salvage. Despite clinical sequencing of known SCID genes, 5 infants (10%) remained without a proven genotype. Whole-exome sequencing failed to solve 4 of these, whereas confirmatory experiments revealed 1 infant to have a defect in a novel SCID gene, B cell lymphoma 11B (BCL11B).
22
In the right columns of Table 4 outcomes after therapy for patients with SCID are summarized. GT, consisting of an autologous transplant of bone marrow-derived hematopoietic stem cells transduced with a vector encoding the correct complementary DNA, was used to a Total infants screened included 91% of infants who were cared for in a regular well-infant nursery or born at home, and 9% who were cared for in a NICU.
b Infants (47% from regular nurseries and 53% from NICUs) with a liquid blood sample tested after 1 positive or 2 incomplete TREC test results made up 0.17% of all births, excluding 20 newborns with TREC-positive test results who either died or were lost to follow-up before a liquid blood sample could be obtained and 2 infants born in another state who had positive TREC screen results and relocated to California for follow-up.
c Infants with ,1500 T cells per mL or ,2% naïve CD3 CD4 CD45RA T helper cells (46% in the regular nursery and 54% in the NICU) made up 0.007% of the population (1 per 15 000 births). This child was successfully treated with GT.
Non-SCID TCL
After ruling out SCID, infants with non-SCID TCL identified by SCID NBS were tracked by participating immunologists in the CDPH long-term follow-up program. 19 Although many infants received a diagnosis in the neonatal period, 22 required further testing over the course of 3 to 18 months to establish a diagnosis (Fig 2) , and 33 others remained idiopathic (Fig 2) . The most frequent non-SCID TCL conditions were congenital syndromes (Fig 2,  Table 5 ). Six infants with syndromes died before flow cytometry could be performed (Supplemental Table 12 ).
See the Supplemental Information for details of patients with non-SCID TCL. The most common syndrome was DiGeorge syndrome, with 47 cases (Fig 2, Table 5 ). More than 90% had partial DiGeorge syndrome, in which T cells rose to age-adjusted reference ranges 12 over time or became adequate as judged by the local immunologist. However, 4 infants with complete DiGeorge syndrome (having persistently ,300 T cells per mL and/or absent naïve helper T cells) received thymus transplants at Duke University in Durham, North Carolina, with 3 surviving for at least 2 years.
25-27 Trisomy 21 accounted for 8 (11%) infants with syndromes; TCL resolved in 3 infants, 3 infants died of nonimmune complications, and 2 were lost to follow-up. All 5 patients with ataxia telangiectasia (AT) were healthy, term newborns from regular nurseries with 800 to 1323 T cells per mL. Rising a-fetoprotein levels after age 6 months led to the identification of deleterious mutations in the AT mutated gene. 28 One infant with AT developed infections requiring IgG infusions during his first year. Three infants with coloboma of the eye, heart defect, atresia choanae, restricted growth and development, genital abnormality, and ear abnormality (CHARGE) syndrome required NICU care for congenital malformations unrelated to the immune system. One was considered for a thymus transplant but died of respiratory failure. The 3 case patients with diabetic embryopathy with TCL were from NICUs and had additional congenital abnormalities. Single patients with rare conditions constituted the remainder of case patients with syndromes (Table 5 ; discussed in the Supplemental Information), including an infant with a novel short-limbed immuno-skeletal dysplasia in whom whole-exome sequencing revealed exostosinlike glycosyltransferase 3 (EXTL3) deficiency. 29 Secondary TCL in 25 case patients (Table 6 ) resolved to normal once excess T-cell losses or suppression of T-cell maturation had been reversed. T-cell losses were associated with vascular leakage, whereas 2 infants had poor T-cell production because of in utero exposure to maternal immunosuppressive medications, fingolimod in 1 and azathioprine in the other. One infant had a thymic teratoma, with T cells normalizing after it was resected. TCL was also occasionally associated with preterm birth (Table 7, Supplemental Tables 9  and 10 ), affecting infants born at 32 weeks' gestation or earlier (median GA at birth: 24 weeks), with a median birth weight of 610 g (range: 300-1720 g). TCL resolved or was improving in 26 of 33 preterm infants who were retested.
Idiopathic TCL included cases for which an underlying condition could not be determined, even after immunologic evaluation and, in many instances, sequencing of gene panels or whole exomes. Of the 33 cases of idiopathic TCL (Table 8) , 13 resolved or were improving, whereas 13 patients had persistent TCL, and 6 patients were lost to follow-up.
DISCUSSION
TREC screening for SCID has been used to establish the feasibility and utility of DNA-based, high-throughput screening, which, like tandem mass spectrometry, has already proven adaptable to additional conditions (including spinal muscular atrophy, as approved in July 2018) for addition to the Recommended Uniform Screening Panel on the basis of a review of evidence.
30 TREC screening in California facilitated the diagnosis of SCID in 50 infants over a 6.5-year period, permitting timely referral to specialized treatment centers for immune-restoring therapy. Sensitivity appears complete in that no cases of typical or early-onset leaky SCID with low T cells are known to have been missed. Indeed, cases of SCID were readily identified by low TRECs, even when maternally engrafted T cells were present, or in Omenn syndrome, when up to several thousand T cells per micro liter had arisen from florid expansion of a small oligoclonal T-cell pool. TRECs are generated in newly differentiated T cells and are not replicated when T cells undergo mitosis. Thus, both maternally transferred cells and proliferating autologous cells have lost TRECs through dilution, and such cells also lack the naïve CD45RA marker and instead express the CD45RO memory maker, both part of the standard California SCID flowcytometry panel. A positive family history of SCID might be expected to make NBS redundant in at least some case patients, 5 but in our experience, obtaining such a history proved problematic. Two of the 50 infants with SCID were from known at-risk pregnancies and had a prenatal diagnosis. However, neonatal medical providers were unaware that 6 other infants had a previous sibling who had been treated for SCID, including 2 siblings who themselves had been identified by SCID NBS in California and received transplants. Although the rate of false-positive TREC screen results was higher in NICUs than in regular nurseries (Fig 1) , 6 of the 50 case patients with true SCID (12%) were in NICUs, proportional to the total number of infants in NICUs (9% of all newborns).
FIGURE 2
Conditions diagnosed in infants with TCL identified by NBS, including 50 infants with typical or leaky SCID (including Omenn syndrome), 72 infants with a final diagnosis of a syndrome associated with T-cell impairment or of a non-SCID primary immunodeficiency disorder, 25 infants with congenital defects associated with secondary TCL, 33 infants with TCL and preterm birth alone, and 55 infants with an initial diagnosis of idiopathic TCL (in whom a syndrome was later diagnosed in 22, leaving 33 idiopathic cases with no underlying defect identified).
a Includes 3 cases of CHARGE syndrome, 3 cases of diabetic embryopathy, and 1 each of CLOVES syndrome, EXTL3 deficiency (immune-skeletal dysplasia with neurodevelopmental abnormalities), Fryns syndrome (multiple anomalies with diaphragmatic defects), Nijmegen breakage syndrome (defect in the DNA repair protein nibrin, causing immune defects, microcephaly, short stature, and malignancy), Noonan syndrome (congenital heart disease, characteristic facial and physical features, and short stature), and RAC2 deficiency (a non-SCID primary immunodeficiency affecting neutrophils and lymphocytes).
b Includes 2 cases of maternal immunosuppressive medication (azathioprine in 1, fingolimod in the other) and 1 case of neonatal teratoma of the thymus.
c Infants with TCL associated with preterm birth alone were grouped by birth weight.
Survival of patients with SCID was 94% at 1 to 8 years of age. Furthermore, 31 of the 46 surviving children (67%) have fully reconstituted B-as well as T-cell immunity, no longer requiring IgG supplementation (Table 1) ; IgG production is expected to recover in additional patients over time, raising the proportion of children fully cured to 75%. The optimal treatment of SCID, HCT from a matched sibling, was available to only 3 infants. As previously published, the children with X-linked SCID who received HCT Autologous GT after low-dose busulfan conditioning is available in clinical trials for patients with ADA-deficient and X-linked SCID who lack matched sibling donors.
8-10
All 8 recipients of GT who were ADA-deficient have had full immune recovery, including independence from IgG infusions, as did the sole recipient of a matched-sibling HCT for ADA-SCID. ERT was used as a bridging therapy between diagnosis and GT for most ADA cases. Four of 14 case patients with X-linked SCID also received GT, although 1 required a subsequent allogeneic HCT for inadequate T-cell recovery. Importantly, and in contrast to previous unconditioned GT or unconditioned HCT with donors other than matched siblings, current GT for both ADA-deficient and X-linked SCID, when preceded by low-dose busulfan chemotherapy, restored both T-and B-cell immunity, allowing 10 of the 12 recipients of GT to discontinue IgG infusions.
The 3 deaths among infants with SCID present a challenge to further improve current therapy. One death followed hepatic sinusoidal obstruction from high-dose chemotherapy, 1 was due to CMV infection, and 1 was due to combined CMV infection and chemotherapy toxicity. Individual targeting of busulfan exposure to account for variable metabolism in young infants may prevent future chemotherapyassociated deaths. 33 CMV is highly pathogenic in the absence of T-cell immunity. Infants with SCID are unlikely to have congenital CMV because maternal primary infection during pregnancy is uncommon; however, they may acquire CMV at or after birth from maternal virus shed into secretions or breast milk because most mothers have serologic evidence of previous CMV exposure. 34 One infant with SCID of unknown genotype may have acquired CMV from breast milk from his mother who was CMV seropositive. On admission to the hospital at 21 days of age, this infant had CMV that was uncontrolled despite antiviral therapy and an accelerated haploidentical paternal HCT. California may have reduced CMV exposure time among infants with SCID by moving the TREC assay to regional laboratories with a faster turnaround. After regionalization, the median age at diagnosis of SCID by lymphocyte subsets for infants without a recognized family history was 8 days (n = 5), compared with 21 days (n = 40) before that time. Further study will be required to establish the sources and best preventive measures to combat CMV infection.
SCID did not occur more frequently in any ethnic group, nor did any California population subgroups demonstrate predominant founder mutations, as previously identified for Navajo American Indians and the Amish.
35,36 However, the frequent occurrence of SCID because of homozygous autosomal recessive mutations reveals a pattern of shared parental ancestry. Of 30 cases of autosomal recessive SCID with mutations identified, 9 (30%) were homozygous (Supplemental Table 11 ).
A late diagnosis in 2 infants who had normal TREC NBS but who proved to have missense defects in the ADA and IL2RG genes, respectively, reveals that SCID has a broad spectrum of mutations and phenotypic presentations. Mutations that are sufficiently leaky to produce some T cells and TRECs may evade neonatal detection. Importantly, raising the TREC cutoff would not have helped to identify either of these case patients by NBS because both had TREC counts well above the designated level requiring follow-up. In addition to diagnosing SCID, TREC NBS has identified non-SCID TCL, permitting intervention to avoid live rotavirus vaccination, which can cause severe diarrheal disease in infants with insufficient T-cell immunity. 20 Secondary and premature TCL cases are expected to resolve, but until they do so, patients are immunocompromised. Although the TCL definition of 1500 CD3 cells per mL as the upper limit provides a medically prudent indication to intervene with immune supervision and avoidance of live viral vaccines, this cutoff does not ensure the identification of all cases of non-SCID, persistent, mild TCL.
Most of the non-SCID syndromes were multisystem disorders summarized in Table 5 ; of all individuals with these syndromes, those with low NBS TRECs and ,1500 T cells per mL were only the ones with the most profound immunologic impairment. Thus, TREC testing is not a screen for DiGeorge syndrome, trisomy 21, or any other syndrome per se. Two-thirds of patients with syndromic TCL had DiGeorge syndrome, usually because of interstitial deletion of chromosome 22q11.2, but also associated with intragenic heterozygous mutations of T-box-containing transcription factor 1 (TBX1), a transcription factor located within the common 22q deletion region. Additionally, some patients with DiGeorge syndrome lacked a known genetic defect. In complete DiGeorge syndrome, some cases of CHARGE syndrome, and some infants of mothers with diabetes, profound TCL is due to the absence of a functional thymus. Urgent intervention to protect such infants from infections is required as in typical SCID, but curative treatment requires a thymus transplant, available only by experimental clinical trial.
26,27 All of the 4 California infants found by NBS to have complete DiGeorge syndrome who were treated with a thymus transplant developed functional T cells, although 1 subsequently died of an unrelated complication. Infants with partial DiGeorge syndrome had stable or rising T cells over time, and those for whom data were available made protective responses to killed vaccines (data not shown).
Thirty-three infants with TCL from preterm birth alone (Table 7) had .2% of their CD4 helper T cells with the naïve CD45RA marker, and their TCL resolved to normal over time. However, longitudinal follow-up was essential to differentiate them from infants with SCID who were born prematurely.
Almost all infants with secondary TCL were cared for in NICUs because of recognized primary conditions, important exceptions being those whose mothers had taken immunosuppressive medication during pregnancy. Although self-limiting, the effects of these medications on infant T cells were profound. For example, despite being contraindicated in pregnancy, fingolimod was taken for multiple sclerosis by 1 woman who was pregnant. This drug is a sphingosine-1-phosphate receptor modulator that acts to sequester lymphocytes in the thymus and lymph nodes, preventing their release. 37 The infant appeared healthy but at 8 days of age, had only 126 T cells, with undetectable naïve T cells, a profile typical of SCID that would require HCT. However, further workup revealed normal T-cell proliferation, and by the age of 2 months, the immune profile had completely resolved without treatment. 
CONCLUSIONS
As an early adopter of TREC screening, the California NBS program has demonstrated not only detection of SCID and clinically important non-SCID TCL with near-complete sensitivity and outstanding specificity but also implementation of highthroughput, DNA-based methodology applicable to other conditions, such as spinal muscular atrophy. The potential harm of live attenuated rotavirus vaccination in infants who are immunodeficient has been averted, strengthening this otherwise beneficial public health measure. The incidence of SCID has proven higher than originally thought, and new disease genes have been discovered in infants identified by SCID NBS. Treatment of SCID detected by NBS has led to 94% survival while revealing areas for future further improvement in targeted chemotherapy and avoidance of CMV infection. 18 With that method, DBS samples with .40 TREC copies per mL of blood (assuming each 3.2 mm punch from a DBS corresponded to 3 mL of liquid blood) were considered normal, as were samples with .25 TRECs per mL on repeated testing. Urgent-positive cases were those with a normal b-actin copy number but ,5 TRECs per mL (Table 1 ).
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The EnLite neonatal TREC kit (PerkinElmer, Inc) was adopted in June 2015, after which testing was conducted in regional laboratories with oversight from the GDL. Standard laboratory validations of the new methodology were applied, including paired testing of unaffected patient samples and testing of retrospective cases previously diagnosed by the NBS program with the original laboratory-developed assay. As a result, the TREC and b-actin copy number thresholds were adjusted to detect the same group of newborns, maximizing sensitivity and identifying all newborns with typical and leaky SCID according to the definitions of the PIDTC. 12 The test also identified infants with ,1500 circulating T cells per mL to undergo evaluation by CDPH immunology associates. An initial normal TREC threshold with the EnLite kit of .22 copies per mL of blood proved, on review and consultation between laboratory directors and immunology associates, to yield excessive falsepositives; the threshold was lowered to .18 copies per mL in February 2017. Unaffected status was assigned after a single DBS obtained at any age (even before 24 hours after birth) had a TREC copy number above the threshold for follow-up. If TRECs were below the threshold, a repeat punch for TRECs and an actin gene segment copy number determination was performed on the same specimen. In contrast with the initial GDL-developed test, DBS samples with #3 TRECs and .55 actin copies per mL of blood were designated as urgent positives, requiring immediate follow-up testing (Table 1) 
Statistical Analysis and Imputations x
2 tests were performed to assess whether the incidence of an abnormal DBS screening result or SCID and non-SCID TCL diagnoses differed according to GA at birth and birth weight and according to ethnicity as designated by parents at the time of NBS. To achieve large enough pools for analysis, ethnicities were grouped as Hispanic, white (non-Hispanic), Asian American, African American, American Indian, other, or multiple race. Two-sided 95% CIs were derived from normal approximation of binomial data or from inversion of cumulative binomial distribution, as appropriate. P , .05 was considered statistically significant.
Newborns with no recorded GA were imputed to be of 40 weeks' GA if they either (1) were designated "term" by physicians or (2) had a birth weight .2500 g and were cared for in wellinfant nurseries. Newborns with no nursery type recorded but born at term weighing .2500 g were imputed to have been in a regular nursery, whereas those born preterm and weighing ,1500 g were imputed have been in a NICU. A total of 36 GA values and 43 nursery assignments were imputed.
RESULTS
All urgent-positive cases in the NICU and all screen-positive non-NICU cases had an immediate liquid blood sample obtained for a complete blood count and flow cytometry. A repeat DBS was obtained for non-urgentpositive cases in the NICU and for incomplete samples. Those newborns in the NICU with persistent nonnormal TREC test results had flow cytometry as soon as possible after the final TREC result. Supplemental Tables 9 and 10 indicate the proportion of infants with abnormal TREC screen results (by GA at birth and by birth weight, respectively) who proved to have ,1500 T cells per mL when a liquid blood sample was subsequently obtained and lymphocyte subsets were measured. The positive predictive value of TRECs for TCL increased with infant maturity at birth.
Fifty cases of SCID were identified, representing 1 per 65 000 births (95% CI 1 per 51 000-1 per 90 000); 44 were from regular nurseries and 6 were from NICUs, equivalent to the proportions of infants without SCID in each nursery type (Fig 1 B and C , Table 4 ). Available genotypes for the SCID cases are shown in Supplemental Table 11 .
The 162 cases of non-SCID TCL were classified into the following categories: congenital syndromes (72 cases), including multisystem congenital abnormalities with TCL and non-SCID single-gene primary immunodeficiencies; TCL resulting from another condition and resolving once that condition was corrected (25 cases); preterm birth alone, in which TCL was self-limited if the infant survived (33 cases); and idiopathic TCL (33 cases). The proportion of infants in each diagnosis category who were from regular nurseries versus NICUs is shown in Fig 1C, and specific conditions within each category are shown in Fig 2. All 33 cases of TCL associated with preterm birth were in NICUs, as were 92% of secondary TCL cases (the exceptions from regular nurseries being 2 infants with TCL due to in utero exposure to immunosuppressive medication prescribed to mothers). Nursery type for syndromic TCL cases varied according to specific conditions: All 5 with AT were in regular nurseries; all 3 with CHARGE syndrome were in NICUs, as were all 3 with diabetic embryopathy and 7 of 8 T-lymphopenic trisomy 21 cases. Cases of DiGeorge syndrome included 19 in regular nurseries and 28 in NICUs, corresponding to the severity of their nonimmune features (primarily conotruncal cardiac defects). Infants with idiopathic TCL, such as those with SCID, were in regular or NICU care proportionate to the overall infant population. Finally, all 19 newborns who were TRECpositive who died and 1 who moved out of state before a liquid blood test could be done were from NICUs (Supplemental Table 12 ).
NON-SCID TCL
The most common syndrome was T-lymphopenic DiGeorge syndrome, with 47 cases (Fig 2, Table 5 ). More than 90% of infants had incomplete DiGeorge syndrome, in which T cells became adequate over time. However, 4 infants with complete DiGeorge syndrome (having persistently ,300 T cells per mL and/or absent naïve helper T cells) were treated with a thymus transplant in a clinical trial at Duke University in Durham, North Carolina. [25] [26] [27] Treatment was performed at 12, 18, 14, and 10 months of age. Three of these patients have survived and are and doing well, with current ages of 3, 5, and 7 years; 1 patient died 4 months after the procedure (at 18 months of age) because of a non-immunerelated cause.
Trisomy 21 accounted for 8 (11%) case patients with syndromic TCL; all but 1 were cared for in NICUs. These infants had only 360 to 1476 total T cells per mL, although all had detectable naïve T cells. One patient had tetralogy of Fallot and had a chylothorax after cardiac surgery, 1 had hydrops and chylothorax at birth, 1 had chylous ascites (also with absent B cells), and 1 had duodenal stenosis requiring surgery. An additional infant with trisomy 21 had transient myeloproliferative disease. TCL resolved in 3 of these infants, 3 died of nonimmune complications, and 2 were lost to follow-up.
All 5 patients with AT were healthy, term newborns from regular nurseries. Their total T cells ranged from 800 to 1323 cells per mL. All had naïve T-cell subsets present and thus, did not require immediate immunerestoring treatment, but rising a-fetoprotein levels after age 6 months led to gene sequencing and identification of deleterious mutations in the AT mutated gene.
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One of these infants required prophylactic antibiotics and IgG infusions during the first year of life because of recurrent respiratory infections, low T-cell numbers, and poor specific antibody production after killed vaccinations.
All 3 infants with CHARGE syndrome were term newborns requiring NICU care for congenital malformations unrelated to the immune system. All had urgent-positive TREC results, and 2 had ,300 CD3 T cells and absent naïve helper T cells. One infant was considered for a thymus transplant but died of respiratory failure. Another has been stable as of 7 months of age, with normal immunoglobulin levels and antibody responses, despite persistent TCL. The third infant had only 304 T cells per mL, but 133 of these were naïve helper T cells, so he was expected to do well without immune intervention.
The 3 case patients with diabetic embryopathy with TCL from NICUs had 988 to 1376 T cells per mL with ample naïve helper T cells (514 to 679/mL). All had additional congenital abnormalities, and 1 patient died of nonimmune complications. TCL resolved in 1 patient, and 1 patient did not have further follow-up recorded.
Single patients with rare conditions constituted the remainder of patients with syndromic cases (Table 5 ). An infant with CLOVES syndrome had an urgent-positive TREC result and only 187 CD3 cells per mL; naïve helper T cells were present at 100 cells per mL. However, he died of respiratory failure associated with large cystic hygromas affecting multiple organs. An infant with short-limbed skeletal dysplasia had 162 cells per mL with detectable naïve cells; whole-exome sequencing revealed a diagnosis of a novel immuno-skeletal dysplasia caused by EXTL3 deficiency. 29 An infant with Fryns syndrome had 1019 T cells per mL, with 520 naïve helper T cells per mL, but died as a result of multiple congenital problems, including diaphragmatic hernia and respiratory failure. Nijmegen breakage syndrome is a known combined immunodeficiency disease caused by mutations in nibrin; 1 infant with low TRECs (924 total T cells per mL), adequate numbers of naïve T cells, but low B cells at 88 cells per mL was diagnosed with this condition after whole-exome sequencing. 38 This infant had additional congenital abnormalities, including schizencephaly, and required IgG infusions. An infant with 120 T cells per mL and absent naïve T cells died with hydrops and chylous chest tube drainage. Noonan syndrome was diagnosed. Finally, RAC2 deficiency has been primarily associated with immunodeficiency with neutrophil dysfunction, but NBS has previously identified TCL in this condition, although the mechanism was not understood. 39 One California infant was also found to have RAC2 deficiency with only 295 T cells per mL; he had 220 naïve helper cells per mL and undetectable naïve cytotoxic T cells. B and NK cell numbers were also low (A.P. Hsu, J.A. Church, et al, unpublished observations).
Secondary TCL was found in 25 case patients (Table 6 ); in infants who survived, TCL resolved to normal once the nonimmune cause of TCL, either increased T-cell losses or suppression of T-cell maturation, had been addressed. The most common findings underlying secondary TCL were related to vascular leakage with extravasation of fluid and lymphocytes from the circulation. There were 6 cases of hydrops that was not part of a syndrome, 2 cases of "third-space" losses, and 1 case of spontaneous chylothorax. Surgical conditions included congenital heart disease and gastrointestinal surgery for gastroschisis, meconium ileus, and gastrointestinal atresia. There were 2 cases of suppression of T-cell production due to in utero exposure to maternal immunosuppressive medications, fingolimod, and azathioprine. One case was associated with a thymic teratoma, with T cells normalizing after it was resected.
TCL is an occasional part of the complex of findings associated with preterm birth, particularly in extremely premature infants and infants who are small for GA (Table 7) . Newborns in this category were born at #32 weeks' gestation (median GA at birth: 24 weeks), and their median birth weight was 610 g (range: 300-1720 g). TCL resolved or was improving in 26 of 33 infants who were retested. Three died without a demonstrated improvement in TCL, and the remaining 4 had no follow-up flow cytometry performed within the NBS program.
Idiopathic TCL includes cases for which an underlying condition could not be determined, even after immunologic evaluation and, in many instances, sequencing of gene panels or whole exomes. Of the 33 cases of idiopathic TCL (Table 8) , 13 resolved or were improving, whereas 13 had persistent TCL. Six infants were lost to follow-up. One infant with no established immune diagnosis had been born at 26 weeks' gestation weighing 1010 g and was treated for suspected CMV with ganciclovir. By 3 months of age he was being weaned from oxygen and gaining weight. He had persistent selective CD4 TCL but a normal naïve CD8 cytotoxic T-cell number. T-cell proliferation to mitogens was normal, and there was uncharacteristically brisk proliferation to candida and tetanus antigens, although he had not received vaccines. He died of respiratory failure at 4 months.
DISCUSSION
SCID did not occur more frequently in any ethnic group, nor did any population subgroups demonstrate predominant founder mutations, as previously identified for Artemisdeficient SCID in Navajo American Indians or for ADA-deficient, IL7R a chain-deficient, and RAG1-deficient SCID in the Amish. 35, 36 Although California has a highly ethnically diverse population, the frequent occurrence of SCID cases due to homozygous autosomal recessive mutations reveals a pattern of shared parental ancestry. Of 30 case patients with autosomal recessive SCID with mutations identified, 9 (30%) had homozygous defects (Supplemental Table 13 ). Although 7 of these case patients were self-identified as Hispanic, with 1 African American and 1 South Asian, differences were not significant, considering the ethnic distribution of births in California.
Of the 72 infants with syndromes identified by TREC NBS, no deaths occurred due to infections, although 8 (11%) infants died of nonimmune complications in the neonatal period (Table 5) . Similarly, among 25 infants with secondary TCL (Table 6) , 4 (16%) remained hospitalized in NICUs and died of their primary condition. A particular subset of infants with secondary TCL was a small proportion of preterm infants with low birth weight (Table 7) . These case patients differed from those with SCID in that .2% of their CD4 helper T cells were of naïve CD45RA phenotype. TCL was attributed to preterm birth if infants did not have syndromic features or an associated TCL-causing condition. Although TCL associated with preterm birth alone resolved to normal over time, follow-up with these case patients was essential to differentiate them from infants who actually had SCID and were coincidentally born prematurely. Two infants with SCID were small for GA, were from twin and triplet pregnancies, and were born at 33 and 35 weeks, respectively; 1 singleton infant with SCID was 1740 g and was born at 35 weeks, and another singleton infant with SCID born weighing 1972 g at 34 weeks had experienced prenatal exposure to methamphetamine and other illicit drugs. Previously not reported Hispanic
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